Ruben de Kanter

6PUBLICATIONS
34CO-AUTHORS
Biologically active moleculesMedical molecular engineering of nucleic acids and proteinsMolecular targetsPharmacogenomicsCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 10, 2024
Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases.

Emmanuel A Meyer, Andrew L Croxford, Carmela Gnerre

|Apr 24, 2024
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Stephane Ferretti, Jacques Hamon, Ruben de Kanter

|Apr 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Andreas Weiss, Edwige Lorthiois, Louise Barys

|Jun 29, 2017
Letter to the Editor, Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.

Ruben de Kanter, Christopher Kohl

|Oct 05, 2016
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.

Amélie Le Bihan, Ruben de Kanter, Iñigo Angulo-Barturen

|Sep 20, 2015
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.

Ruben de Kanter, Patricia N Sidharta, Stéphane Delahaye

Pageof 1

Frequent Collaborators

2 joint publications

Hans Voshol

1 joint publications

Jeremy Burrows

1 joint publications

Nina F Gnädig

1 joint publications

Caroline L Ng